References
- Ellenberg SS, Foulkes MA, Midthun K, Goldenthal KL. Evaluating the safety of new vaccines: summary of a workshop. Am J Public Health 2005;95(5):800-7
- Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980;303(15):833-41
- Black SB, Shinefield HR, Fireman B, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61 080 children. Pediatr Infect Dis J 1991;10(2):97-103
- Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19(3):187-95
- Bines J. Intussusception and rotavirus vaccines. Vaccine 2006;24(18):3772-6
- Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human–bovine (WC3) reassortant rotavirus vaccine. N Eng J Med 2006;354(1):23-33
- Ward RL, Bernstein DI. Rotarix: a rotavirus vaccine for the world. Clin Infect Dis 2009;48(2):222-8
- Available from: www.cdc.gov/pneumococcal/surveillance.html
- Grijalva CG, Poehling KA, Nuorti JP, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006;118(3):865-73
- Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. PIDJ 2002;21(9):810-15
- Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immuniszation with PCVin the USA: a time-series analysis. Lancet 2007;369(9568):1179-86
- Lieu TA, Ray GT, Black SB, et al. Projected cost effectiveness of pneumococcal conjugate vaccine in infants and young children. JAMA 2000;283(11):1460-8
- Ray GT, Whitney CG, Fireman BH, et al. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. PIDJ 2006;25(6):494-501
- Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human–bovine):WC3) reassortant rotavirus vaccine. N Eng J Med 2006;354(1):23-33
- Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;376(9741):615-23
- Storsaeter J, Hallander H, Farrington CP, et al. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 1990;8(5):457-61
- Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Eng J Med 2012;367(11):1012-19
- Available from: http://cvi.asm.org/content/17/5/840/F1.large.jpg
- Oster P, Lennon D, O’Hallahan J, et al. MeNZB™: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005;23(17):2191-6
- Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. In: Vaccines for Pandemic Influenza. Springer Berlin Heidelberg, Heidelberg, Germany; 2009. p. 43-82
- Lieu TA, Kulldorff M, Davis RL, et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med care 2007;45(10):S89-95
- Available from: http://ecdc.europa.eu/en/press/news/_layouts/forms/News_DispForm.aspx?List=8db7286c-fe2d-476c-9133-18ff4cb1b568&ID=915
- Available from: www.who.int/vaccine_safety/initiative/en/
- Lambert LC. Pertussis vaccine trials in the 1990s. J Infect Dis 2014;209(Suppl 1):S4-9
- Future II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007;196(10):1438-46
- GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6· 4 years. Lancet 2009;374(9706):1975-85
- Strom BL. Pharmacoepidemiology. 2nd Edition. J Wiley and Sons, New York City, NY, USA; 1994